Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Reinstadler, SJ; Kronbichler, A; Reindl, M; Tiller, C; Holzknecht, M; Oberhollenzer, F; Kaser, A; Gauckler, P; Stiermaier, T; Feistritzer, HJ; Mayr, A; Gizewski, ER; Rezar, R; Bugger, H; Eller, K; Eitel, I; Schneider, S; Mayer, G; Thiele, H; Bauer, A; Metzler, B; Lechner, I, , CRP-STEMI, Investigators.
Selective C-reactive protein apheresis in ST-elevation myocardial infarction: Design and rationale of the randomized CRP-STEMI trial.
Am Heart J. 2025; Doi: 10.1016/j.ahj.2025.07.067
PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Bugger Heiko Matthias; Eller Kathrin
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: Despite the effectiveness of primary percutaneous coronary intervention (PCI) in treating ST-elevation myocardial infarction (STEMI), myocardial salvage is often incomplete, resulting in large infarct size and an increased risk of heart failure and mortality. Inflammation is involved in this process, with C-reactive protein (CRP) potentially contributing to infarct expansion. Whether selective CRP apheresis in addition to standard care can reduce infarct size in STEMI remains to be determined. TRIAL DESIGN: Selective C-reactive protein apheresis in ST-elevation myocardial infarction (CRP-STEMI) is an investigator-initiated, randomized, open-label (outcome assessor blinded), multicenter trial investigating whether selective CRP apheresis using the PentraSorb®-CRP system, in addition to standard care, can reduce infarct size in STEMI patients undergoing PCI within 12 hours of symptom onset. The trial will enroll 202 patients at five tertiary care centers in Austria and Germany, randomized 1:1 to either the intervention group (standard care + CRP apheresis) or the control group (standard care). In the intervention group, CRP apheresis will be performed on days 1, 2, and 3 post-PCI. The primary endpoint is infarct size as assessed by late gadolinium enhanced cardiac magnetic resonance at 5 ± 2 days after PCI. OUTLOOK: CRP-STEMI is the first randomized trial to investigate whether selective CRP apheresis, as an adjunct to standard care, can effectively reduce infarct size in acute STEMI patients. TRIAL REGISTRATION: CRP-STEMI, NCT04939805, is registered at https://clinicaltrials.gov/study/ NCT04939805.